Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Autoimmnue and Respiratory Conditions
4.2.2 Research for Safer New Anti-Inflammatory Drugs
4.3 Market Restraints
4.3.1 Side Effects of Anti-Inflammtory Drugs
4.3.2 Patent Expiration
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Arthritis
5.1.2 Chronic obstructive pulmonary disease (COPD)
5.1.3 Multiple Sclerosis
5.1.4 Inflammatory bowel disease (IBD)
5.1.5 Asthma
5.1.6 Tendonitis
5.1.7 Other Treatments
5.2 By Drug Class
5.2.1 Anti-Inflammatory Biologics
5.2.2 Nonsteroidal anti inflammatory drugs (NSAIDS)
5.2.3 Corticosteroids
5.2.4 Immune-selective anti-inflammatory derivative (ImSAID)
5.2.5 Other Drug Classes
5.3 By Sales Channel
5.3.1 Prescription
5.3.2 Over the Counter (OTC)
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Amgen Inc.
6.1.3 GlaxoSmithKline PLC
6.1.4 Johnson & Johnson
6.1.5 Novartis International AG
6.1.6 F. Hoffmann-La Roche AG
6.1.7 AbbVie Inc
6.1.8 AstraZeneca PLC
6.1.9 Merck & Company, Inc.
6.1.10 Eli Lily and Company


7 MARKET OPPORTUNITIES AND FUTURE TRENDS